中珠醫療(600568.SH):潛江製藥生產的利巴韋林注射液產品銷售收入對公司營收影響極小
格隆匯2月7日丨中珠醫療(600568.SH)公佈,公司股票於2020年2月5日、2月6日、2月7日連續三個交易日內收盤價格漲幅偏離值累計超到20%。
經公司自查,受疫情影響,部分下屬子公司根據各省市相關政策存在開工延後等情況,該情況將對公司生產經營產生一定影響,目前公司正根據疫情及市場變動情況適時調整生產經營策略等方式,進一步降低此次疫情帶來的影響。除此以外,公司目前生產經營正常,未發生重大調整或變化,不存在影響公司股票交易價格異常波動的重大事宜。
公司關注到近日市場有對公司相關產品的傳聞,現對相關情況説明並風險提示如下:
經核實,公司持有 91.67%的控股子公司湖北潛江製藥股份有限公司(“潛江製藥”),目前生產的利巴韋林注射液產品2018年銷售收入為174萬元,佔潛江製藥2018年營業收入的5.2%,佔公司營業收入的0.3%,2019年1-9月銷售收入為11萬元,佔潛江製藥2019年1-9月營業收入的0.4%,佔公司2019年1-9月營業收入的0.03%,其銷售收入對公司營業收入的影響極小,對公司整體經營業績影響極小。
公司主營業務為房地產、醫藥及醫療器械的研發、生產及銷售,除上述藥品外,無其他藥品可以用於預防、治療此次新型冠狀病毒感染肺炎。敬請廣大投資者注意投資風險。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.